Cellivery Therapeutics, Inc. is a Korea-based company principally engaged in the research and development of medicines and biotherapeutics. The Company develops biotherapeutics capable of entering cells in vivo through proprietary therapeuticmolecule systemic delivery technology (TSDT). The Company research and develop therapeutic drug candidates such as Parkinsonâs disease treatment, pancreatic cancer and solid cancer treatment, bone formation promoter, as well as advanced obesity & type II diabetes mellitus; new drugs for research including DNA recombinase and reprogramming factors (RFs).

Employees

Sector

Biotechnology & Medical Research

Calendar

2024-11-12 - Q3 2024 Earnings Release (Projected)

More about the company

Income Statement and Estimates

More financial data

End-of-day quote Korea S.E. Other stock markets 2023-03-23			5-day change	1st Jan Change
6,680.00 ^KRW	-29.91%		-.--%	-.--%

2023	Cellivery Therapeutics, Inc.(KOSDAQ:A268600) dropped from S&P Global BMI Index	CI
2021	Cellivery Therapeutics, Inc. acquired Ajin Clean Co., Ltd. from SVAJ Holdings for KRW 14.2 billion.	CI

Capitalization	248B 185M 251M	P/E ratio 2022	-4.02x	P/E ratio 2023	-7.51x
Enterprise value	293B 219M 297M	EV / Sales 2022	20.8x	EV / Sales 2023	15.4x
Free-Float	86.18%	Yield 2022 *	-	Yield 2023	-

Cellivery Therapeutics, Inc.(KOSDAQ:A268600) dropped from S&P Global BMI Index	23-04-05	CI
Cellivery Therapeutics, Inc. acquired Ajin Clean Co., Ltd. from SVAJ Holdings for KRW 14.2 billion.	21-11-16	CI
Cellivery Therapeutics, Inc. agree to acquire Ajin Clean Co., Ltd. for KRW 14.9 billion.	21-11-15	CI
Cellivery Therapeutics, Inc. announced that it has received KRW 38.9997004 billion in funding	21-10-14	CI
Cellivery Therapeutics to Raise Nearly $17 Million Through Stock Sale	21-09-30	MT
Cellivery Therapeutics, Inc. announced that it expects to receive KRW 38.9997004 billion in funding	21-09-29	CI
Cellivery Therapeutics to Raise $13 Million from Stock Offering	21-09-23	MT
Cellivery Therapeutics, Inc. announced that it has received KRW 43.9988081 billion in funding from a group of investors	20-08-18	CI
Cellivery Therapeutics, Inc. announced that it expects to receive KRW 43.9988081 billion in funding from a group of investors	20-08-05	CI
Cellivery Therapeutics, Inc.(KOSDAQ:A268600) added to S&P Global BMI Index	19-03-18	CI
Cellivery Therapeutics, Inc has completed an IPO in the amount of KRW 28.5 billion.	18-11-08	CI
Cellivery Therapeutics, Inc has filed an IPO.	18-07-11	CI

Director	Title	Age	Since
Dae-Woong Cho CEO	Chief Executive Officer	56	14-03-13
Sun-Hong Kwon BRD	Director/Board Member	50	21-03-28
Byung-Hwa Lee AUD	Comptroller/Controller/Auditor	60	19-03-21

Cellivery Therapeutics, Inc. Stock

Equities

A268600

KR7268600004

Biotechnology & Medical Research

Valuation: Cellivery Therapeutics, Inc.

Latest news: Cellivery Therapeutics, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Cellivery Therapeutics, Inc.

ETFs: Cellivery Therapeutics, Inc.

Bio Therapeutic Drugs

Financials

Company Profile

Income Statement and Estimates

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi. ($)
CELLIVERY THERAPEUTICS, INC.	-29.91%	-.--%	-.--%	-79.38%	185M
REGENERON PHARMACEUTICALS, INC.	+0.45%	-3.22%	+36.94%	+78.49%	123B
VERTEX PHARMACEUTICALS INCORPORATED	+0.84%	-0.80%	+36.73%	+148.92%	122B
ARGENX SE	+0.74%	+5.29%	+1.46%	+76.27%	32.18B
BIONTECH SE	-1.35%	+11.51%	-15.84%	-69.66%	23.93B
BEIGENE, LTD.	+6.80%	+11.93%	+0.91%	-42.03%	21B
GENMAB A/S	-2.37%	-3.26%	-31.35%	-35.00%	17.38B
WUXI APPTEC CO., LTD.	+3.35%	+0.39%	-49.42%	-72.63%	14.82B
VAXCYTE, INC.	-2.31%	+4.03%	+116.62%	+327.04%	14.38B
SUMMIT THERAPEUTICS INC.	-1.18%	+89.17%	+1,292.64%	+259.75%	16.64B
Average	-2.54%	+6.43%	+138.87%	+59.18%	38.47B
Weighted average by Cap.	+0.61%	+3.93%	+79.53%	+90.86%

	2022	2023
Net sales	23.16B 17.3M 23.46M	18.86B 14.09M 19.11M
Net income	-75.16B -56.14M -76.14M	-32.57B -24.33M -32.99M
Net Debt	48.13B 35.95M 48.76M	44.76B 33.44M 45.34M